

VisuXL®

Eye drops for premium dry eye relief and recovery



The **NEXT generation** eye drops
in the relief of dry eye symptoms

VISUfarma
the eye health company

Dry eye symptom impacts the quality of life¹


Dry eye symptom affects social, psychological functioning, daily activities and workplace productivity

A number of questionnaires have been developed to quantify the impact of dry eye symptom on various aspects of patients' quality of life.¹ The most recognized of which is the Ocular Surface Disease Index Questionnaire (OSDI, Allergan Inc.)²



The **NEXT** generation eye drops in the relief of dry eye symptom

VisuXL[®] contains a unique combination of key ingredients




References

1. Uchino M, Schaumberg DA. Dry Eye Disease: Impact on Quality of Life and Vision. *Curr Ophthalmol Rep* 2013;1(2):51-57.
2. Amparo F et al. Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye. *Ophthalmol* 2015;122(7):1498-1503.
3. VisuXL Instructions For Use. Last revised 7/2020.
4. Muzzi M, Mancucci R. Poster presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting. February 16-19, 2017. Florence, Italy.
5. Fogagnolo P, et al. *Ophthalmologica* 2013; 229: 26-31.

Clinical trial verified that people with dry eye symptom used with VisuXL[®] experience greater relief compared to HA eye drops³



VisuXL[®] helps users in relieving of dry eye symptom



	Day 0	Day 15	Day 30	Day 90
VisuXL [®]	50.6 ± 17.3	47.9 ± 20.7	33.9 ± 9.9*	34.6 ± 17.9*†
0.15% HA	49.1 ± 11.5	45 ± 12.2	40.2 ± 15.1*	41.5 ± 11.8*

● VisuXL[®] ● 0.15% HA


i Graph adapted from Postorino E.I. *et al.* 2018.

*P<0.05 vs Baseline and Day 15; †P=0.05 vs 0.15% HA at the same time.
 OSDI = Ocular Surface Disease Index.

Study design:³

Randomized, single-masked, parallel-group, comparative study investigated the efficacy and safety, in the relief of mild to moderate dry eye symptom, of an ophthalmic solution containing XLHA with CoQ10 (VisuXL, n=20) versus a formulation containing 0.15% HA (Ocuyal, n=20). Eye drops were administered 4 times daily for 12 weeks.

OSDI score⁷



VisuXL[®] vs HA

	HyloForte	HyloTear	Optive Fusion	Thealoz Duo
Claim used				
Type of HA				
Bottle cost				
Additional ingredients				
Times per day use				
Preservative				


References

3. Postorino E, et al. Efficacy of eye drops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. *Eur J Ophthalmol* 2018;28(1):25-31.
 7. Ocular Surface Disease Index. Allergan 1995.

VisuXL[®] eye drops help to restore a healthy ocular surface³



People with dry eye symptom used with VisuXL[®] experience a highly statistically significant 4 fold reduction in corneal impairment



	Day 0	Day 15	Day 30	Day 90
VisuXL [®]	2.2 ± 0.4	2.5 ± 0.5	1.6 ± 0.7*	1.4 ± 0.8*, **
0.15% HA	2.1 ± 0.7	2.5 ± 0.8	2 ± 0.8	2.3 ± 0.6

● VisuXL[®] ● HA

*p<0.001 vs. visits at days 0 and 15;
 **p=0.005 vs. HA at the same time of observation.
 Graph adapted from Postorino EI et al. 2018.

A 0.8 reduction in Oxford scale is a 4 fold reduction in corneal impairment

There are varying degrees of corneal impairment:

Panel	Grade	Criteria
A	0 (Absent)	≤ A
B	I (Minimal)	≤ panel B > A
C	II (Mild)	≤ panel C, > B
D	III (Moderate)	≤ panel D, > C
E	IV (Marked)	≤ panel E, > D
>E	V (Severe)	> panel E

Table adapted from Bron AG Cornea 2003.⁶

References


- Postorino E, et al. Efficacy of eye drops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol 2018;28(1):25-31.
- Bron AJ et al. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22(7): 640-650.

Users can experience in relieving of dry eye symptom from 2 drops per day⁴



2 Drops

Residence time on ocular surface 3x longer than HA*⁵



*Based on residence time of cross-linked HA following instillation onto ocular surface of rabbit eyes

Cross-linked HA provides lasting relief to your dry eye symptom^{4,5}

Prescribing VisuXL[®] eye drops

- VisuXL[®] is an ophthalmic, lubricating and antioxidant solution without preservatives, composed of cross-linked hyaluronic acid salt, Coenzyme Q10 and Vitamin E TPGS⁴

Available in:^{4,8}

- 10 ml multidose bottle, sterile for 180 days
- Can be used while wearing contact lenses. It does not alter their characteristics and can even hydrate soft lenses⁴
- 1-2 drops of VisuXL[®] should be applied to the conjunctival sac of each eye 2 times per day or as directed⁴
- VisuXL[®] should be used at least five minutes after the administration of other medicinal products⁴

References

4. VisuXL Instructions For Use. Last revised 7/2020.

5. Muzzi M, Mencucci R. Poster presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting. February 16-19, 2017. Florence, Italy.

8. VisuXL Unit Dose Instructions for Use. Last revised 12/2018.

VisuXL®

The **NEXT** generation eye drops in the relief of dry eye symptom



Relieve

VisuXL® users feel better compared to HA alone ³



Restore

VisuXL® supports the restoration of a healthy ocular surface ³



2 Drops

VisuXL® provides lasting relief from 2 drops a day ⁴



Prescribe VisuXL® today

Distributor:

KERRY
PHARMA
嘉里醫藥

+852 2211 3799 +852 2408 8905
HK.KerryPharma.Order@kerrylogistics.com
<https://www.kerrypharma.com.hk>

VISUfarma
the eye health company

References

3. Postorino E, et al. Efficacy of eye drops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol 2018;28(1):25-31.

4. VisuXL Instructions For Use. Last revised 7/2020.